|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
ACC006口服溶液与标准化疗方案联合在晚期鳞状非小细胞肺癌患者中的临床研究
[Translation] Clinical study of ACC006 oral solution combined with standard chemotherapy in patients with advanced squamous non-small cell lung cancer
主要目的是观察ACC006与标准化疗方案联合使用的耐受性和安全性,确定剂量限制性毒性(DLT)。次要目的是评价ACC006联合化疗的药代动力学特征,初步观察有效性。
[Translation] The primary purpose is to observe the tolerability and safety of ACC006 in combination with standard chemotherapy regimens and determine dose-limiting toxicity (DLT). The secondary purpose is to evaluate the pharmacokinetic characteristics of ACC006 combined with chemotherapy and preliminarily observe the effectiveness.
100 Clinical Results associated with Jiangsu Edison Biotechnology Co., Ltd.
0 Patents (Medical) associated with Jiangsu Edison Biotechnology Co., Ltd.
100 Deals associated with Jiangsu Edison Biotechnology Co., Ltd.
100 Translational Medicine associated with Jiangsu Edison Biotechnology Co., Ltd.